SB-480848 (GlaxoSmithKline)

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


SB-480848 is a reversible lipoprotein-associated phospholipase A 2 inhibitor under development by GlaxoSmithKline for the potential treatment of atherosclerosis. Phase II trials with SB-480848 are currently underway.

Original languageEnglish
Pages (from-to)348-351
Number of pages4
JournalCurrent Opinion in Investigational Drugs
Issue number3
StatePublished - Mar 2004


Dive into the research topics of 'SB-480848 (GlaxoSmithKline)'. Together they form a unique fingerprint.

Cite this